Comparative Pharmacology
Head-to-head clinical analysis: PALYNZIQ versus STRENSIQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PALYNZIQ versus STRENSIQ.
PALYNZIQ vs STRENSIQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PALYNZIQ (pegvaliase-pqpz) is a recombinant phenylalanine ammonia lyase conjugated to polyethylene glycol. It converts phenylalanine to trans-cinnamic acid and ammonia, reducing blood phenylalanine levels in patients with phenylketonuria.
Human recombinant tissue-nonspecific alkaline phosphatase (TNSALP) that hydrolyzes inorganic pyrophosphate (PPi), a natural inhibitor of hydroxyapatite crystal growth, thereby promoting bone mineralization.
2.4 mg subcutaneously once daily.
6 mg/kg administered subcutaneously once weekly.
None Documented
None Documented
Approximately 60–80 hours (terminal half-life); supports weekly dosing regimen.
Terminal elimination half-life approximately 5.1 days (123 hours) in adults; supports once-weekly subcutaneous dosing for sustained pharmacodynamic effect.
Renal (predominantly as intact pegylated enzyme); less than 5% fecal. No active metabolites.
Renal (primarily via proteolytic catabolism into small peptides and amino acids); negligible biliary or fecal elimination.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy